The State Drug Administration has approved Sanofifashuk for uric acid control in children with leukemia and lymphoma

recently, Sanofi China announced that the NationalDrug(The Supervisory Authority has recently approved Faschuk (injection with Labrihai) for children with leukemia, lymphoma patients with urinary acid level control, these patients already have hyperuric acidemia or have a high tumor load, there is a tumor chemotherapy caused by tumor cell dissolution and lead to secondary plasma uric acid level increased risk to reduce the risk of tumor dissolution syndrome, to ensure the continuity of treatmentthis time approved in China, Fasuk can effectively control the presence of hyperuric acidemia in children with tumor dissolution syndromebecause there was no previous effectivedrug(treatment options), in which children develop hyperulate acidemia during chemotherapy, acute kidney failure can only be prevented through hemodialysis"
Professor Wu Minxuan of Beijing Children's Hospital affiliated with Capital Medical University points out that if left untreated, large amounts of uric acid can easily form crystalline precipitation in the kidneys, which can lead to electrolyte disorders, acute kidney failure and even deathHowever, hemodialysis is not only time-consuming and burdensome, but also the need to stop chemotherapy during dialysis, which can lead to a break in the course of cancer treatment, which is undoubtedly worse for children undergoing chemotherapythree multicenter clinicaltrial(n s 265, including 246 children and 19 adult patients), Faschuk has a powerful, rapid acid reduction effectin children with high risk of lymphoma/leukemia with tumor-dissolved syndrome, Faschuk showed a significant therapeutic advantage over the traditional drug, the otherulpurinol, in controlling uric acid levelsOf the patients who were effectively evaluated, 92% of the patients had plasma uric acid concentrations controlled within four hoursOther data show that 90% of children treated with Faschuk lasted up to 7 days